Key points are not available for this paper at this time.
Tumor growth response to eribulin and copanlisib, either alone or in combination, in additional TNBC PDX models
Guo et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: